Literature DB >> 7505677

A PCR-based method for the analysis of human CD44 splice products.

D H van Weering1, P D Baas, J L Bos.   

Abstract

CD44 is a transmembrane glycoprotein involved in the interaction between cells and extracellular matrix. Several variant forms of CD44 exist, which differ from each other in the composition of both the intra- and extracellular domain of the protein. Post-translational modification and alternative RNA processing are responsible for this variation. Recently, it was found that certain variant CD44 proteins, containing extra sequences in the extracellular domain of the protein, are involved in metastatic spread of tumor cells. Variant CD44 proteins are also involved in immunological functions of T and B cells. A large variety of alternatively spliced CD44 mRNAs can be expressed by cells. We have developed a method for the analysis of CD44 mRNAs present in the cell. This reverse transcription-polymerase chain reaction (RT-PCR)-based method can be used to analyze the exon composition of each major CD44 mRNA species present in the cell. In this study we describe the analysis of CD44 mRNAs isolated from six different human cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505677     DOI: 10.1101/gr.3.2.100

Source DB:  PubMed          Journal:  PCR Methods Appl        ISSN: 1054-9803


  35 in total

1.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

2.  Role of CD44 and its v7 isoform in staphylococcal enterotoxin B-induced toxic shock: CD44 deficiency on hepatic mononuclear cells leads to reduced activation-induced apoptosis that results in increased liver damage.

Authors:  Robert J McKallip; Michael Fisher; Ursula Gunthert; Andras K Szakal; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  The normal structure and function of CD44 and its role in neoplasia.

Authors:  R J Sneath; D C Mangham
Journal:  Mol Pathol       Date:  1998-08

4.  CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix.

Authors:  C A Henke; U Roongta; D J Mickelson; J R Knutson; J B McCarthy
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 5.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

6.  Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

7.  Met receptors induce Sam68-dependent cell migration by activation of alternate extracellular signal-regulated kinase family members.

Authors:  Alessia Locatelli; Carol A Lange
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

8.  Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44.

Authors:  K Svee; J White; P Vaillant; J Jessurun; U Roongta; M Krumwiede; D Johnson; C Henke
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

9.  Two different functions for CD44 proteins in human myelopoiesis.

Authors:  J Moll; S Khaldoyanidi; J P Sleeman; M Achtnich; I Preuss; H Ponta; P Herrlich
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor.

Authors:  Shlomo Nedvetzki; Itshak Golan; Nathalie Assayag; Erez Gonen; Dan Caspi; Micha Gladnikoff; Avner Yayon; David Naor
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.